FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316405247> ?p ?o ?g. }

• W2316405247 endingPage "1385" @default.
• W2316405247 startingPage "1374" @default.
• W2316405247 abstract "Overexpression of the high affinity neurotensin receptor 1 (NTSR1), demonstrated in several human cancers, has been proposed as a new marker for human ductal pancreatic carcinoma and as an independent factor for poor prognosis for ductal breast cancer, head and neck squamous cell carcinoma, and non-small cell lung cancer. The aim of the present study was to develop new DOTA-neurotensin analogues for positron emission tomography (PET) imaging with (68)Ga and for targeted radiotherapy with (90)Y or (177)Lu. We synthesized a DOTA-neurotensin analogue series. Two of these peptides bear two sequence modifications for metabolic stability: DOTA-NT-20.3 shares the same peptide sequence as the previously described DTPA-NT-20.3. In the sequence of DOTA-NT-20.4, the Arg(8)-Arg(9) bond was N-methylated instead of the Pro(7)-Arg(8) bond in DOTA-NT-20.3. An additional sequence modification was introduced in DOTA-LB119 to increase stability. A spacer was added between DOTA and the peptide sequence to increase affinity. Binding to HT29 cells, which express NTSR1, in vivo stability, and biodistribution of the various analogues were compared, and the best candidate was used to image tumors of various sizes with the microPET in mice. (111)In-DOTA-NT-20.3, in spite of a relatively high uptake in kidneys, showed specific tumor uptake and elevated tumor to other organ uptake ratios. High contrast images were obtained at early time points after injection that allowed tumor detection at a time interval postinjection appropriate for imaging with the short-lived radionuclide (68)Ga. (111)In-DOTA-NT-20.4 displayed inferior binding to HT29 cells and reduced tumor uptake. (111)In-DOTA-LB119 displayed at early time points a significantly lower renal uptake but also a lower tumor uptake than (111)In-DOTA-NT-20.3, although binding to HT29 cells was similar. (68)Ga-DOTA-NT-20.3 displayed higher tumor uptake than (68)Ga-DOTA-LB119 and allowed the detection of very small tumors by PET. In conclusion, DOTA-NT-20.3 is a promising candidate for (68)Ga-PET imaging of neurotensin receptor-positive tumors. DOTA-NT-20.3 may also be considered for therapy, as the yttrium-labeled peptide has higher affinity than that of the indium-labeled one. A prerequisite for therapeutic application of this neurotensin analogue would be to lower kidney uptake, for example, by infusion of basic amino acids, gelofusin, or albumin fragments, to prevent nephrotoxicity, as with radiolabeled somatostatin analogues." @default.
• W2316405247 created "2016-06-24" @default.
• W2316405247 creator A5000510379 @default.
• W2316405247 creator A5004255429 @default.
• W2316405247 creator A5013569394 @default.
• W2316405247 creator A5034294981 @default.
• W2316405247 creator A5048612636 @default.
• W2316405247 creator A5051743021 @default.
• W2316405247 creator A5054659506 @default.
• W2316405247 creator A5064093167 @default.
• W2316405247 creator A5064623290 @default.
• W2316405247 date "2011-07-01" @default.
• W2316405247 modified "2023-10-16" @default.
• W2316405247 title "Novel DOTA-Neurotensin Analogues for ¹¹¹In Scintigraphy and ⁶⁸Ga PET Imaging of Neurotensin Receptor-Positive Tumors" @default.
• W2316405247 cites W1480715733 @default.
• W2316405247 cites W1497075656 @default.
• W2316405247 cites W1966286364 @default.
• W2316405247 cites W1971430341 @default.
• W2316405247 cites W1975602223 @default.
• W2316405247 cites W1978039785 @default.
• W2316405247 cites W1979166795 @default.
• W2316405247 cites W1985502316 @default.
• W2316405247 cites W1986723218 @default.
• W2316405247 cites W1987234788 @default.
• W2316405247 cites W1996496419 @default.
• W2316405247 cites W2000506699 @default.
• W2316405247 cites W2001364673 @default.
• W2316405247 cites W2002852719 @default.
• W2316405247 cites W2008301567 @default.
• W2316405247 cites W2015551880 @default.
• W2316405247 cites W2031658504 @default.
• W2316405247 cites W2038039985 @default.
• W2316405247 cites W2043102080 @default.
• W2316405247 cites W2043635035 @default.
• W2316405247 cites W2044357064 @default.
• W2316405247 cites W2045742325 @default.
• W2316405247 cites W2052716045 @default.
• W2316405247 cites W2055626631 @default.
• W2316405247 cites W2058130105 @default.
• W2316405247 cites W2078680567 @default.
• W2316405247 cites W2094135147 @default.
• W2316405247 cites W2095634557 @default.
• W2316405247 cites W2102874648 @default.
• W2316405247 cites W2105388123 @default.
• W2316405247 cites W2112330217 @default.
• W2316405247 cites W2112838511 @default.
• W2316405247 cites W2121521155 @default.
• W2316405247 cites W2131897082 @default.
• W2316405247 cites W2138287287 @default.
• W2316405247 cites W2148617171 @default.
• W2316405247 cites W2166132430 @default.
• W2316405247 cites W2324535690 @default.
• W2316405247 cites W4234670614 @default.
• W2316405247 doi "https://doi.org/10.1021/bc200078p" @default.
• W2316405247 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21662976" @default.
• W2316405247 hasPublicationYear "2011" @default.
• W2316405247 type Work @default.
• W2316405247 sameAs 2316405247 @default.
• W2316405247 citedByCount "49" @default.
• W2316405247 countsByYear W23164052472012 @default.
• W2316405247 countsByYear W23164052472013 @default.
• W2316405247 countsByYear W23164052472014 @default.
• W2316405247 countsByYear W23164052472015 @default.
• W2316405247 countsByYear W23164052472016 @default.
• W2316405247 countsByYear W23164052472017 @default.
• W2316405247 countsByYear W23164052472018 @default.
• W2316405247 countsByYear W23164052472019 @default.
• W2316405247 countsByYear W23164052472020 @default.
• W2316405247 countsByYear W23164052472021 @default.
• W2316405247 countsByYear W23164052472022 @default.
• W2316405247 countsByYear W23164052472023 @default.
• W2316405247 crossrefType "journal-article" @default.
• W2316405247 hasAuthorship W2316405247A5000510379 @default.
• W2316405247 hasAuthorship W2316405247A5004255429 @default.
• W2316405247 hasAuthorship W2316405247A5013569394 @default.
• W2316405247 hasAuthorship W2316405247A5034294981 @default.
• W2316405247 hasAuthorship W2316405247A5048612636 @default.
• W2316405247 hasAuthorship W2316405247A5051743021 @default.
• W2316405247 hasAuthorship W2316405247A5054659506 @default.
• W2316405247 hasAuthorship W2316405247A5064093167 @default.
• W2316405247 hasAuthorship W2316405247A5064623290 @default.
• W2316405247 hasConcept C118303440 @default.
• W2316405247 hasConcept C170493617 @default.
• W2316405247 hasConcept C178790620 @default.
• W2316405247 hasConcept C185592680 @default.
• W2316405247 hasConcept C197404232 @default.
• W2316405247 hasConcept C202751555 @default.
• W2316405247 hasConcept C2775842073 @default.
• W2316405247 hasConcept C2777307743 @default.
• W2316405247 hasConcept C2777807558 @default.
• W2316405247 hasConcept C2778976297 @default.
• W2316405247 hasConcept C2779281246 @default.
• W2316405247 hasConcept C2779931791 @default.
• W2316405247 hasConcept C2989005 @default.
• W2316405247 hasConcept C502942594 @default.
• W2316405247 hasConcept C55493867 @default.
• W2316405247 hasConcept C71924100 @default.
• W2316405247 hasConceptScore W2316405247C118303440 @default.

• next